Stock ANNX ANNEXIN PHARMACEUTICALS AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Market Closed - Nasdaq Stockholm
Other stock markets
 08:35:08 02/05/2024 pm IST 		5-day change 1st Jan Change
0.308 SEK +2.67% Intraday chart for Annexin Pharmaceuticals AB +11.59% +18.46%
30/04 Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals CI
12/04 Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Annexin Pharmaceuticals AB Announces Success in the Cancer Initiative
Annexin Pharmaceuticals AB Announces Promising Signals of Effect in RVO- Study
Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023
Annexin Pharmaceuticals AB Auditor Raises 'Going Concern' Doubt
Annexin Reports First Imaging- Study Results in Retinal Vein Occlusion
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Annexin Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022
Annexin Pharmaceuticals AB Appoints Dr. Alain Thibault as Therapeutic Area Head of Oncology
Annexin Pharmaceuticals Doses First Patient in Phase 2 Trial of Retinal Vein Occlusion Treatment
Annexin Pharmaceuticals AB Announces First Patient Dosed in Annexin's Phase 2 Study in Retinal Vein Occlusion
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANNX Stock
  4. News Annexin Pharmaceuticals AB
  5. Other languages